Hepatitis B Diagnostics Market to Reach USD 4.2 Billion by 2035, Registering a CAGR of 6.7%

Hepatitis B Diagnostics Market to Reach USD 4.2 Billion by 2035, Registering a CAGR of 6.7%

The global Hepatitis B Diagnostics Market was valued at USD 2.1 Billion in 2025 and is projected to reach USD 4.2 Billion by 2035, growing at a compound annual growth rate (CAGR) of 6.7% during the forecast period 2025–2035.

The global Hepatitis B Diagnostics Market is experiencing steady growth as healthcare providers increasingly focus on early detection, accurate diagnosis, and long-term monitoring of hepatitis B virus (HBV) infections. Growing adoption of high-sensitivity immunoassays (HSI), molecular diagnostics, and point-of-care testing technologies is improving diagnostic accuracy and accessibility.

Market Overview

Hepatitis B diagnostics include serological and molecular testing technologies used to detect, confirm, and monitor hepatitis B virus infections. Common diagnostic tests include HBsAg, anti-HBc, HBeAg, and PCR-based HBV DNA quantification.

The evolution of hepatitis B diagnostics from traditional radioimmunoassays to automated enzyme immunoassays (EIA), chemiluminescent immunoassays (CLIA), and advanced nucleic acid amplification tests has significantly improved diagnostic sensitivity and reliability.

These diagnostic solutions are widely used in prenatal screening, blood donor testing, occupational health programs, and population-level disease surveillance. Increasing awareness of early diagnosis and the need for continuous monitoring of chronic hepatitis B infections are supporting market development.

Download Free Sample Report: Hepatitis B Diagnostics Market

Growth Drivers & Trends

Several factors are supporting the growth of the global Hepatitis B Diagnostics Market.

Rising prevalence of hepatitis B infections is a major growth driver. The substantial global disease burden and the large undiagnosed population are encouraging governments and healthcare organizations to strengthen screening, early detection, and disease surveillance programs.

Technological advancements in high-sensitivity immunoassays (HSI) are improving the detection of low-level viral antigens and HBV DNA, supporting earlier identification of infections and reducing false-negative results.

Artificial intelligence and laboratory automation are transforming diagnostic workflows through improved biomarker interpretation, faster processing, and reduced manual errors.

Another important trend is the increasing adoption of point-of-care (POC) testing, which improves access to hepatitis B diagnostics in remote and underserved communities.

Additionally, multiplex testing platforms and next-generation sequencing (NGS) are creating opportunities for viral genotyping, resistance mutation monitoring, and improved disease management.

Market Segmentation

By Diagnostic Purpose

  • Screening
  • Blood Donor Screening
  • Antenatal Screening
  • Community / Population Screening
  • Occupational Screening
  • Acute HBV Diagnosis
  • Chronic HBV Diagnosis
  • Disease Monitoring

By Biomarker / Test Target

  • HBsAg
  • Anti-HBs
  • Total Anti-HBc
  • IgM Anti-HBc
  • HBeAg
  • Others

By Test Modality / Technology

  • Immunoassays (Serology)
  • Rapid Diagnostic Tests (RDTs)
  • ELISA / EIA
  • CLIA / ECLIA
  • Chemiluminescent Microparticle Immunoassay (CMIA)
  • Real-Time PCR (qPCR)
  • Digital PCR
  • Isothermal Amplification
  • Sanger Sequencing
  • Next-Generation Sequencing (NGS)
  • Multiplex Molecular Panels

By Product Type

  • Instruments / Analyzers
  • Reagents and Kits
  • Consumables
  • Software / Informatics

By Sample Type

  • Whole Blood
  • Serum
  • Plasma
  • Dried Blood Spot (DBS)
  • Others

By End User / Testing Site

  • Hospitals and Hospital Laboratories
  • Independent / Private Diagnostic Laboratories
  • Blood Banks / Transfusion Centers
  • Public Health Laboratories
  • Clinics and Primary Care Centers
  • Research Institutes / Academic Laboratories
  • Others

By Patient / Risk Group

  • Pregnant Women
  • Newborns / Infants
  • General Adult Population
  • Healthcare Workers
  • Hemodialysis Patients
  • Immunocompromised Patients
  • People Living with HIV
  • Household and Sexual Contacts of HBV-Positive Individuals
  • Others

Regional Analysis

North America holds a leading position in the global Hepatitis B Diagnostics Market, supported by advanced diagnostic infrastructure, widespread availability of automated laboratory platforms, and established screening programs.

Asia Pacific is expected to remain an important growth region due to its high hepatitis B disease burden and increasing government and private investments in diagnostic infrastructure.

Japan is also an important market, with increasing adoption of preventive healthcare policies, routine screening initiatives, and advanced diagnostic technologies.

Get the Complete Market Report – Buy Now: Hepatitis B Diagnostics Market Report

Competitive Landscape

The global Hepatitis B Diagnostics Market is characterized by established diagnostic technology providers and manufacturers offering immunoassay platforms, molecular testing systems, reagents, and diagnostic kits.

Competition is primarily driven by technological innovation, diagnostic sensitivity, automation capabilities, product affordability, testing speed, and the expansion of point-of-care diagnostic solutions.

Key Players

  • Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • DAAN Gene Co. Ltd.
  • Bio-Rad Laboratories Inc.
  • DiaSorin SpA
  • Siemens Healthineers
  • QIAGEN NV
  • bioMérieux SA
  • Xiamen Innovax Biotech Co. Ltd.
  • MedMira Inc.
  • Grifols SA
  • Hologic Inc.

Recent Developments

Technological advancements in high-sensitivity immunoassays, automated laboratory platforms, point-of-care testing, and next-generation sequencing are shaping the Hepatitis B Diagnostics Market.

These innovations are supporting improvements in diagnostic sensitivity, testing accessibility, viral genotyping, and long-term hepatitis B disease monitoring.

Frequently Asked Questions (FAQ)

  1. What is the projected market size and CAGR of the Hepatitis B Diagnostics Market?

The global Hepatitis B Diagnostics Market was valued at USD 2.1 Billion in 2025 and is projected to reach USD 4.2 Billion by 2035, growing at a CAGR of 6.7% during 2025–2035.

  1. What are the major factors driving the Hepatitis B Diagnostics Market?

Major growth drivers include increasing hepatitis B prevalence, expanding screening programs, technological advancements in high-sensitivity immunoassays, and rising demand for early and accurate diagnosis.

  1. Which technologies are commonly used in hepatitis B diagnostics?

Major technologies include enzyme immunoassays (EIA), chemiluminescent immunoassays (CLIA), rapid diagnostic tests, real-time PCR, digital PCR, and next-generation sequencing.

  1. Which regions are important in the Hepatitis B Diagnostics Market?

North America and Asia Pacific are important regional markets. North America benefits from advanced diagnostic infrastructure, while Asia Pacific is supported by a high disease burden and increasing diagnostic investments.

  1. Who are the major companies operating in the Hepatitis B Diagnostics Market?

Major companies include Hoffmann-La Roche Ltd., Abbott Laboratories, DAAN Gene Co. Ltd., Bio-Rad Laboratories Inc., DiaSorin SpA, Siemens Healthineers, QIAGEN NV, bioMérieux SA, and Grifols SA.

Related Reports

About Us

At BrandEssence®, we help companies enhance their strategies by providing actionable insights. We use scientific research to investigate consumer views, perceptions, and expectations regarding an existing or proposed product or service launch. A variety of factors influence the success of a product and service launch, and scientific research helps organizations understand opinions, perceptions, and expectations.

The team at BrandEssence® applies market research methodologies across industries and domains, using research tools and analytical approaches to generate actionable market insights.

Contact Us

BrandEssence® Market Research and Consulting Pvt Ltd

Phone No.: +918975852287

Email Id: [email protected]

Website: https://brandessenceresearch.com/

Avatar photo
Author: Weida Isles
Writer and editor of the PNP Media.